Annis Gardner Whiting Capital Advisors’s VistaGen Therapeutics VTGN Stock Holding History

Annis Gardner Whiting Capital Advisors’s Portfolio VTGN Stock Details VTGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$343	Buy	+600	New	+$365	﹤0.01%	1232

Other funds holding VTGN

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Annis Gardner Whiting Capital Advisors's VTGN Position: Q1 2026 in Review

Annis Gardner Whiting Capital Advisors opened a new position in VistaGen Therapeutics (VTGN) in Q1 2026: 600 shares worth $343. The stake represents ﹤0.01% of the portfolio and ranks #1232 among its holdings.

56 funds tracked by Wall St. Rank hold VTGN as of Q1 2026.

Annis Gardner Whiting Capital Advisors held 600 shares of VistaGen Therapeutics worth $343 as of Q1 2026.
VistaGen Therapeutics was a new Annis Gardner Whiting Capital Advisors position in Q1 2026.
VistaGen Therapeutics made up ﹤0.01% of Annis Gardner Whiting Capital Advisors's portfolio in Q1 2026, its #1232 holding.
56 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q1 2026.

Based on Annis Gardner Whiting Capital Advisors's 13F filing for Q1 2026, filed 6 May 2026.